21,662 reports of this reaction
2.8% of all DUPILUMAB reports
#8 most reported adverse reaction
DRY SKIN is the #8 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 21,662 FDA adverse event reports linking DUPILUMAB to DRY SKIN. This represents approximately 2.8% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience dry skin should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRY SKIN is a less commonly reported adverse event for DUPILUMAB, but still significant enough to appear in the safety profile.
In addition to dry skin, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to dry skin in FDA adverse event reports:
DRY SKIN has been reported as an adverse event in 21,662 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRY SKIN accounts for approximately 2.8% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience dry skin while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.